Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures

Trial Profile

Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy; Generalised seizures; Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Eisai Korea
  • Most Recent Events

    • 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
    • 24 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top